New! Sign up for our free email newsletter.
Science News
from research organizations

T-cells could be made into better cancer killers by increasing their protein production

Date:
May 20, 2020
Source:
Medical University of South Carolina
Summary:
Researchers have developed a technique to quantify protein production in immune cells known as T-cells, which typically target and kill cancer cells. However, when near a tumor, most T cells produce little protein and lose their cancer-fighting ability, and the new technique could help clarify why. Interventions could then be developed to restore protein production and allow T cells in the vicinity of tumors to become better cancer killers.
Share:
FULL STORY

A team of scientists from Hollings Cancer Center at the Medical University of South Carolina (MUSC) has developed a novel flow cytometry technique that can, for the first-time, quantify protein production in T-cells. T cells are immune cells that surveil the body and can effectively target and kill cancer cells. However, when T cells are in the vicinity of a tumor, cancer cells sap their energy, leading to a decrease in their protein production. This change leads to T cells losing their tumor-killing ability.

The new technique, developed by the MUSC team, can be used to monitor protein production in T cells and understand how it becomes depressed in the tumor microenvironment. Interventions could then be developed to restore T cells' protein production and ability to control tumor growth. The team, led by Jessica E. Thaxton, Ph.D., recently reported its findings in a priority brief in Cancer Immunology Research. Thaxton is an assistant professor in the departments of Orthopaedics and Physical Medicine and Microbiology and Immunology at MUSC and a member of Hollings Cancer Center, a National Cancer Institute designated cancer center.

"This study reveals our first attempt at trying to understand how T cells undergo the process of making proteins," explained Thaxton. "Before this paper or before this technology, scientists had very little idea how much protein T cells make. It was a shot in the dark. But now we have quantitative data that shows how much protein T cells make, and we can begin to ask questions like, 'Which proteins?' and 'How are they made?'"

In the past four years, the team observed more than 50 human tumors, and in most tumors, they noticed the existence of T cells that made very little protein. This finding led them to surmise that there are T cells unable to make proteins residing in tumors. According to Thaxton, the new technology will help them to monitor these T cells and reawaken their protein production machinery and cancer-fighting ability.

"This paper establishes that T cells that are able to make protein in tumors have phenomenal ability to control tumor growth," explained Thaxton. "We ultimately want to remodel the existing T cell population in tumors, and that is really where our laboratory is headed."

To understand more fully protein production in T cells in tumors, the scientists used two different types of signaling molecules (cytokines) called IL-15 and IL-2. It has been established in other studies that T cells treated with IL-15 control tumor growth very well, but those conditioned with IL-2 do so poorly. The team found that T cells conditioned with IL-15 were able to make proteins in the tumor microenvironment and in tumors, whereas IL-2 conditioned T cells experienced diminished protein production in tumors.

These results will help scientists to understand how they can reawaken tumor T-cells and increase their protein production, thereby enhancing their ability to control tumor growth. Thaxton believes that a simple strategy of combining a modulator that changes the way that T cells generate energy will allow T cells to experience sustained protein production in tumors and produce more effective immunotherapy treatments for patients.

Unlike many current immunotherapies, which can be quite expensive, this approach would be cost-effective and thus a more realistic strategy for treating cancer patients from all walks of life.

Thaxton believes that the current study is the very first set of experiments that begins to delineate the role of protein production in anti-tumor immunity.

"There is a lot more in store that we are now uncovering from this basic first set of experiments," explained Thaxton. "This paper is a model of our first insight into how protein production is regulated in T cells, and we are working on which parts of the regulation are the most important for tumor control."


Story Source:

Materials provided by Medical University of South Carolina. Original written by Alhaji Janneh. Note: Content may be edited for style and length.


Journal Reference:

  1. Katie E. Hurst, Kiley A. Lawrence, Rob A. Robino, Lauren E. Ball, Dongjun Chung, Jessica E. Thaxton. Remodeling Translation Primes CD8 T-cell Antitumor Immunity. Cancer Immunology Research, 2020; 8 (5): 587 DOI: 10.1158/2326-6066.CIR-19-0516

Cite This Page:

Medical University of South Carolina. "T-cells could be made into better cancer killers by increasing their protein production." ScienceDaily. ScienceDaily, 20 May 2020. <www.sciencedaily.com/releases/2020/05/200520191419.htm>.
Medical University of South Carolina. (2020, May 20). T-cells could be made into better cancer killers by increasing their protein production. ScienceDaily. Retrieved October 31, 2024 from www.sciencedaily.com/releases/2020/05/200520191419.htm
Medical University of South Carolina. "T-cells could be made into better cancer killers by increasing their protein production." ScienceDaily. www.sciencedaily.com/releases/2020/05/200520191419.htm (accessed October 31, 2024).

Explore More

from ScienceDaily

RELATED STORIES